BC-043 Director of Community Outreach, Debra Melamed speaks with Regional Sales Director of Foundation Medicine, Amy Macalintal about their comprehensive genomic profiling testsOctober 16, 2018 | Author: BeatCancer.org
These tests are for people with a cancer diagnosis that are considering chemotherapy, have had traditional treatment that has failed them, or for someone who has had a reoccurrence. Their tests detect genomic alterations on cancer tumor cells’ DNA. They help your doctor to identify more potential treatment options than other available tests because they analyze all genes known to be relevant in human cancers. The test report includes the identified genomic alterations and provides information on which targeted therapies, immunotherapies, or clinical trials are a match.
They offer 3 different test that must be ordered by your doctor, FoundationOne Heme (for leukemia, lymphoma, and myeloma), FoundationACT (liquid biopsy when a tissue biopsy is not possible), and FoundationOne Cdx (primarily for non-small-cell lung, breast, prostate, colorectal, melanoma, and ovarian cancers)